SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.71
−1.16%Research · Aug 25, 2026
Plasma Proteomics Shifts From Plex Count to Cross-Platform Accuracy
Independent cross-platform data now ranks plasma proteomics platforms: Seer cites 13.5% of its targets unlikely to concur, against 39% and over 45% for rivals.